drugset / Trial / NCT03964207
A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
RandomizedCrossoverOpen-labelTreatment
Summary
The objective of this study is to investigate the patient acceptability/preference of Respimat® compared with Handihaler® in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) to demonstrate the superiority of Respimat®.
Timeline
- Start
- 2019-11-25
- Primary completion
- 2021-10-19
- Completion
- 2021-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tiotropium | Other / unclassified | 5 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 18 ug | Inhaled |